We assessed models of variance explained to compare the relative utility of amyloid PET, tau PET, and plasma P-tau217 in predicting cognitive decline, including baseline demographics, cognitive and functional measures, and treatment assignment in the model. The gene discussed is MAPT; the disease is Mental deterioration.